Demographics and clinical characteristics of the patients.

<p>Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; SD, standard deviation.</p

Expression of SRSF1, SRSF2 and phosphorylated SRSF2 proteins in NSCLCs.

<p>A, Representative immunostaining from frozen section of normal lung parenchyma and lung cancer tissue with anti SRSF1 (a, b, c), anti SRSF2 (d,e,f) and anti phospho-SRSF2 (g, h, i) antibodies [(a, d, g) normal lung; (b, e, h) ADC; (c, f, i) SCC; immunoperoxidase and haematoxylin counterstaining]. B, Representative western blots demonstrating overexpression of SRSF1 and SRSF2 proteins in lung tumors compared with their matched normal lung tissues. (NL, normal lung; ADC, adenocarcinoma; SCC, squamous cell carcinoma).</p

SRSF1 scores according to the clinico-pathological parameters in NSCLC subtypes.

<p>Distribution of SRSF1 scores according to the tumor size (A), the nodal status (B), the presence of metastases at distance (C) and the pTNM stage (D), in all the tumors (left panels, NSCLC) and in histological subtypes (right panels, ADC and SCC). Statistical analysis was done using Mann-Whitney’s U test.</p

Immunohistochemical analysis of SRPK1 and SRPK2 proteins expression in non-small cell lung cancer according to histological subtype.

<p>Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC, non-small cell lung carcinoma. Immunostaining scores were calculated by multiplying the number of labeled cells (0–100%) by the level of intensity (1–3). According to this, tumor samples were grouped into three classes (see ‘<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046539#s2" target="_blank">Materials and Methods</a>’ section): class 0 (normal expression, as compared to normal lung), class 1 (moderate overexpression) and class 2 (high overexpression). Statistical analysis was done using Fisher’s exact test.</p

Relationship between SRPK2 protein expression and phospho-SRSF2 status in NSCLC subtypes.

<p>A, Distribution of phospho-SRSF2 scores in tumors displaying normal (class 0), moderate (class +) or overexpression (class ++) of SRPK2, in all the tumors (left panels, NSCLC) and in histological subtypes (right panels, ADC and SCC). B, Distribution of SRPK2 scores according to the tumor stage, in all the tumors (left panels, NSCLC) and in histological subtypes (right panels, ADC and SCC). Statistical analysis was done using Mann-Whitney’s U test.</p

Relationship between SRSF2 overexpression and its phosphorylated status in NSCLC subtypes.

<p>Distribution of phospho-SRSF2 scores in tumors displaying either normal SRSF2 expression (class 0) or SRSF2 overexpression (class +), in all the tumors (left panels, NSCLC) and in histological subtypes (right panels, ADC and SCC). Statistical analysis was done using Mann-Whitney’s U test.</p

Expression of SRSF2 and its phosphorylated form according to the clinico-pathological parameters in NSCLC subtypes.

<p>Distribution of SRSF2 and phospho-SRSF2 scores according to the tumor size (A, C) and the stage (B, D), in all the tumors (left panels, NSCLC) and in histological subtypes (right panels, ADC and SCC). Statistical analysis was done using Mann-Whitney’s U test.</p

SRSF1 overexpression increases resistance to carboplatin and paclitaxel.

<p>(A) H358 cells were treated for 24 hours with increasing amounts of etoposide, carboplatin or paclitaxel as indicated. SRSF1 protein level was analyzed by western blotting. Tubulin was used as a loading control. (B) 96-hours cell viability assays were performed in H358-Ctl cells (grey symbols) or H358-SRSF1 clones (black symbols) treated or not with increasing amounts of carboplatin, paclitaxel or etoposide. Results are expressed as the percentage of survival cells compared to untreated cells. Mean value of three independent experiments ± standard deviation performed in triplicate are presented.</p